Cargando…

The Atrial Fibrillation Better Care (ABC) Pathway and Clinical Outcomes in Patients with Atrial Fibrillation: the Prospective Murcia AF Project Phase II Cohort

BACKGROUND: The Atrial fibrillation Better Care (ABC) pathway was proposed for a more holistic or integrated care approach to atrial fibrillation (AF) management. We investigated whether adherence with the ABC pathway reduced the risk of adverse clinical outcomes in real-world AF patients starting v...

Descripción completa

Detalles Bibliográficos
Autores principales: Rivera-Caravaca, José Miguel, Roldán, Vanessa, Martínez-Montesinos, Lorena, Vicente, Vicente, Lip, Gregory Y.H., Marín, Francisco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9905403/
https://www.ncbi.nlm.nih.gov/pubmed/35411538
http://dx.doi.org/10.1007/s11606-022-07567-5
_version_ 1784883796802273280
author Rivera-Caravaca, José Miguel
Roldán, Vanessa
Martínez-Montesinos, Lorena
Vicente, Vicente
Lip, Gregory Y.H.
Marín, Francisco
author_facet Rivera-Caravaca, José Miguel
Roldán, Vanessa
Martínez-Montesinos, Lorena
Vicente, Vicente
Lip, Gregory Y.H.
Marín, Francisco
author_sort Rivera-Caravaca, José Miguel
collection PubMed
description BACKGROUND: The Atrial fibrillation Better Care (ABC) pathway was proposed for a more holistic or integrated care approach to atrial fibrillation (AF) management. We investigated whether adherence with the ABC pathway reduced the risk of adverse clinical outcomes in real-world AF patients starting vitamin K antagonist (VKAs) therapy. METHODS: Prospective cohort study including AF outpatients starting VKA therapy from July 2016 to June 2018. Patients were considered as adherent if all ABC pathway criteria (A: Avoid stroke; B: Better symptom control; and C: Cardiovascular risk factors/comorbidities management) were fulfilled. The primary endpoints were all-cause mortality, net clinical outcomes (NCOs), major adverse cardiovascular events (MACE), and composite thrombotic/thromboembolic events at 2 years. RESULTS: We enrolled 1045 patients (51.6% female; median age 77 [70–83] years). Of these, 63.0% (658) were adherent to the ABC pathway and 37% (387) were considered non-adherent. Compared to non-adherent patients, those who were ABC adherent had lower event rates for all-cause mortality (13.76 vs. 6.56; p<0.001), NCOs (19.65 vs. 11.94; p<0.001), and MACE (11.88 vs. 7.75; p=0.006) during the follow-up. Adjusted Cox regression analyses demonstrated that the ABC pathway adherent care reduced the risks of all-cause mortality (aHR 0.57, 95% CI 0.42–0.78), NCOs (aHR 0.72, 95% CI 0.56–0.92), and cardiovascular mortality (aHR 0.54, 95% CI 0.32–0.90). Event-free survivals for all-cause mortality, NCOs (both log-rank p-values <0.001), and MACE (log-rank p-value = 0.004) were also higher in ABC pathway adherent patients. CONCLUSIONS: In this real-world prospective cohort of AF patients starting VKA therapy, adherence to the ABC pathway management at baseline significantly reduced the risk of NCOs, all-cause mortality, and cardiovascular death at 2 years. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11606-022-07567-5.
format Online
Article
Text
id pubmed-9905403
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-99054032023-02-08 The Atrial Fibrillation Better Care (ABC) Pathway and Clinical Outcomes in Patients with Atrial Fibrillation: the Prospective Murcia AF Project Phase II Cohort Rivera-Caravaca, José Miguel Roldán, Vanessa Martínez-Montesinos, Lorena Vicente, Vicente Lip, Gregory Y.H. Marín, Francisco J Gen Intern Med Original Research BACKGROUND: The Atrial fibrillation Better Care (ABC) pathway was proposed for a more holistic or integrated care approach to atrial fibrillation (AF) management. We investigated whether adherence with the ABC pathway reduced the risk of adverse clinical outcomes in real-world AF patients starting vitamin K antagonist (VKAs) therapy. METHODS: Prospective cohort study including AF outpatients starting VKA therapy from July 2016 to June 2018. Patients were considered as adherent if all ABC pathway criteria (A: Avoid stroke; B: Better symptom control; and C: Cardiovascular risk factors/comorbidities management) were fulfilled. The primary endpoints were all-cause mortality, net clinical outcomes (NCOs), major adverse cardiovascular events (MACE), and composite thrombotic/thromboembolic events at 2 years. RESULTS: We enrolled 1045 patients (51.6% female; median age 77 [70–83] years). Of these, 63.0% (658) were adherent to the ABC pathway and 37% (387) were considered non-adherent. Compared to non-adherent patients, those who were ABC adherent had lower event rates for all-cause mortality (13.76 vs. 6.56; p<0.001), NCOs (19.65 vs. 11.94; p<0.001), and MACE (11.88 vs. 7.75; p=0.006) during the follow-up. Adjusted Cox regression analyses demonstrated that the ABC pathway adherent care reduced the risks of all-cause mortality (aHR 0.57, 95% CI 0.42–0.78), NCOs (aHR 0.72, 95% CI 0.56–0.92), and cardiovascular mortality (aHR 0.54, 95% CI 0.32–0.90). Event-free survivals for all-cause mortality, NCOs (both log-rank p-values <0.001), and MACE (log-rank p-value = 0.004) were also higher in ABC pathway adherent patients. CONCLUSIONS: In this real-world prospective cohort of AF patients starting VKA therapy, adherence to the ABC pathway management at baseline significantly reduced the risk of NCOs, all-cause mortality, and cardiovascular death at 2 years. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11606-022-07567-5. Springer International Publishing 2022-04-11 2023-02 /pmc/articles/PMC9905403/ /pubmed/35411538 http://dx.doi.org/10.1007/s11606-022-07567-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Research
Rivera-Caravaca, José Miguel
Roldán, Vanessa
Martínez-Montesinos, Lorena
Vicente, Vicente
Lip, Gregory Y.H.
Marín, Francisco
The Atrial Fibrillation Better Care (ABC) Pathway and Clinical Outcomes in Patients with Atrial Fibrillation: the Prospective Murcia AF Project Phase II Cohort
title The Atrial Fibrillation Better Care (ABC) Pathway and Clinical Outcomes in Patients with Atrial Fibrillation: the Prospective Murcia AF Project Phase II Cohort
title_full The Atrial Fibrillation Better Care (ABC) Pathway and Clinical Outcomes in Patients with Atrial Fibrillation: the Prospective Murcia AF Project Phase II Cohort
title_fullStr The Atrial Fibrillation Better Care (ABC) Pathway and Clinical Outcomes in Patients with Atrial Fibrillation: the Prospective Murcia AF Project Phase II Cohort
title_full_unstemmed The Atrial Fibrillation Better Care (ABC) Pathway and Clinical Outcomes in Patients with Atrial Fibrillation: the Prospective Murcia AF Project Phase II Cohort
title_short The Atrial Fibrillation Better Care (ABC) Pathway and Clinical Outcomes in Patients with Atrial Fibrillation: the Prospective Murcia AF Project Phase II Cohort
title_sort atrial fibrillation better care (abc) pathway and clinical outcomes in patients with atrial fibrillation: the prospective murcia af project phase ii cohort
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9905403/
https://www.ncbi.nlm.nih.gov/pubmed/35411538
http://dx.doi.org/10.1007/s11606-022-07567-5
work_keys_str_mv AT riveracaravacajosemiguel theatrialfibrillationbettercareabcpathwayandclinicaloutcomesinpatientswithatrialfibrillationtheprospectivemurciaafprojectphaseiicohort
AT roldanvanessa theatrialfibrillationbettercareabcpathwayandclinicaloutcomesinpatientswithatrialfibrillationtheprospectivemurciaafprojectphaseiicohort
AT martinezmontesinoslorena theatrialfibrillationbettercareabcpathwayandclinicaloutcomesinpatientswithatrialfibrillationtheprospectivemurciaafprojectphaseiicohort
AT vicentevicente theatrialfibrillationbettercareabcpathwayandclinicaloutcomesinpatientswithatrialfibrillationtheprospectivemurciaafprojectphaseiicohort
AT lipgregoryyh theatrialfibrillationbettercareabcpathwayandclinicaloutcomesinpatientswithatrialfibrillationtheprospectivemurciaafprojectphaseiicohort
AT marinfrancisco theatrialfibrillationbettercareabcpathwayandclinicaloutcomesinpatientswithatrialfibrillationtheprospectivemurciaafprojectphaseiicohort
AT riveracaravacajosemiguel atrialfibrillationbettercareabcpathwayandclinicaloutcomesinpatientswithatrialfibrillationtheprospectivemurciaafprojectphaseiicohort
AT roldanvanessa atrialfibrillationbettercareabcpathwayandclinicaloutcomesinpatientswithatrialfibrillationtheprospectivemurciaafprojectphaseiicohort
AT martinezmontesinoslorena atrialfibrillationbettercareabcpathwayandclinicaloutcomesinpatientswithatrialfibrillationtheprospectivemurciaafprojectphaseiicohort
AT vicentevicente atrialfibrillationbettercareabcpathwayandclinicaloutcomesinpatientswithatrialfibrillationtheprospectivemurciaafprojectphaseiicohort
AT lipgregoryyh atrialfibrillationbettercareabcpathwayandclinicaloutcomesinpatientswithatrialfibrillationtheprospectivemurciaafprojectphaseiicohort
AT marinfrancisco atrialfibrillationbettercareabcpathwayandclinicaloutcomesinpatientswithatrialfibrillationtheprospectivemurciaafprojectphaseiicohort